Every 8-K that Xenon Pharmaceuticals Inc (XENE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow XENE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XENE filings page.
Xenon Pharmaceuticals reported Q2 2026 results alongside significant clinical and regulatory progress for its lead KV7 modulator azetukalner. After a successful pre-NDA meeting with the FDA, the company plans to submit a New Drug Application for azetukalner in focal onset seizures in the third quarter of 2026. Phase 3 trials continue across epilepsy (X-TOLE3, X-ACKT), major depressive disorder (X-NOVA2 and X-NOVA3) and bipolar depression (X-CEED), with topline X-NOVA2 data anticipated in the first half of 2027.
Cash, cash equivalents and marketable securities totaled $1,245.1 million as of June 30, 2026, compared with $586.0 million as of December 31, 2025, and management expects this to fund operations into 2029. For Q2 2026, Xenon reported a net loss of $110.7 million and no revenue, versus a $84.7 million net loss in Q2 2025, as research and development expenses increased to $99.2 million and general and administrative expenses to $23.9 million, driven by late-stage azetukalner programs, pain studies, manufacturing, and higher personnel costs. Other income rose to $11.8 million, primarily from higher interest income, and 96,752,884 common shares and 2,931,293 pre-funded warrants were outstanding as of June 30, 2026.
Xenon Pharmaceuticals Inc. reported results of its annual meeting of shareholders held on June 2, 2026. Shareholders approved a new 2026 Equity Incentive Plan to replace the prior 2014 plan, following the Board of Directors’ recommendation.
Shareholder turnout was high, with 90,399,636.29 common shares, representing approximately 93.54% of shares entitled to vote, present or represented by proxy. All director nominees were elected, the advisory "say‑on‑pay" vote on executive compensation was approved, and shareholders supported holding this advisory vote every one year. Shareholders also approved the appointment of PricewaterhouseCoopers LLP as independent auditor and authorized the audit committee to set the auditor’s remuneration.
Xenon Pharmaceuticals reported a larger net loss in Q1 2026 as it ramps late‑stage neuroscience programs but highlighted pivotal clinical progress and a strengthened balance sheet. The company posted a net loss of $102.3 million (vs. $65.0 million a year ago), driven by higher research and development and general and administrative expenses and the absence of prior collaboration revenue.
Cash, cash equivalents, and marketable securities rose to $1.34 billion as of March 31, 2026, after raising $130.0 million via an at‑the‑market program and $707.6 million through a public offering, extending cash runway into 2029. Xenon reported positive Phase 3 X‑TOLE2 data for azetukalner in focal onset seizures, with a placebo‑adjusted median percent change in monthly seizure frequency of -42.7% at 25 mg, and plans a New Drug Application submission in Q3 2026. Multiple additional Phase 3 studies in epilepsy and mood disorders, as well as Phase 1 pain programs targeting NaV1.7 and KV7, continue to enroll or progress.
Xenon Pharmaceuticals Inc. amended and restated its 2025 Inducement Equity Incentive Plan to expand the share pool used for new-hire equity awards. The maximum number of common shares reserved under the plan increased from 900,000 to 1,175,000 shares, subject to adjustment under the plan’s terms.
These shares may be granted as nonstatutory stock options, stock appreciation rights, restricted stock units, restricted stock, or performance awards, and are intended as inducements for individuals being hired or rehired as employees of Xenon or its subsidiaries. In line with Nasdaq Listing Rule 5635(c)(4), shareholder approval was not obtained for this inducement-only plan.
Xenon Pharmaceuticals Inc. outlined key details for its 2026 annual meeting of shareholders. The meeting is scheduled for June 2, 2026, with a record date for notice and voting of April 7, 2026, which is also the beneficial ownership determination date.
Holders of Xenon common shares are entitled to receive notice of and vote at the meeting. The company will not mail materials directly to non-objecting beneficial owners but will pay for distribution to objecting beneficial owners. Xenon is using notice-and-access for both registered and non-registered investors, and the related information was also submitted through a SEDAR+ filing furnished as Exhibit 99.1.
Xenon Pharmaceuticals Inc. completed a large equity financing, raising approximately $707.7 million in net proceeds from an underwritten public offering of common shares and pre-funded warrants. The company sold 12,236,843 common shares and pre-funded warrants to purchase 877,194 common shares, plus an additional 1,710,526 common shares after underwriters fully exercised their 30-day option.
The public offering price was $57.00 per common share and $56.9999 per pre-funded warrant, with underwriters purchasing at discounted prices. The pre-funded warrants have a $0.0001 exercise price, may be exercised for cash or on a cashless basis, and include a beneficial ownership cap initially set at 4.99%, adjustable by the holder up to 19.99% with advance notice. The warrants also provide protections and alternate consideration in certain major corporate transactions.
Xenon Pharmaceuticals reported positive Phase 3 results from its X-TOLE2 study of azetukalner in adults with focal onset seizures. The trial met its primary endpoint, with median percent change in monthly seizure frequency of -53.2% for the 25 mg dose and -34.5% for 15 mg, versus -10.4% for placebo, giving a placebo-adjusted effect of -42.7% for 25 mg. Key secondary goals were also achieved, including responder rates (≥50% seizure reduction) of 54.8% for 25 mg and 37.6% for 15 mg, versus 20.8% for placebo. Safety and tolerability were generally consistent with prior studies, though dizziness and other nervous system side effects were more frequent at higher doses. Xenon plans to submit a New Drug Application to the FDA for focal onset seizures in the third quarter of 2026 and is preparing for potential commercialization.
Xenon Pharmaceuticals Inc. filed a prospectus supplement to register $400,000,000 of common shares for issuance under its at-the-market equity offering sales agreement with Jefferies and Stifel. This keeps the company’s ATM capacity available for future issuances under an existing sales framework.
The new prospectus supplement replaces and supersedes a prior prospectus, and the earlier offering has been terminated. As of the filing date, the company had already sold $291,084,564 in common shares under the sales agreement pursuant to the prior prospectus.
Xenon Pharmaceuticals reported a larger net loss in 2025 as it ramped up late-stage clinical development of its lead epilepsy and mood-disorder drug azetukalner. Net loss was $345.9 million for 2025, compared with $234.3 million in 2024, driven mainly by higher research and development spending.
Research and development expenses rose to $300.9 million in 2025 from $210.4 million, reflecting multiple Phase 3 studies in epilepsy, major depressive disorder and bipolar depression, as well as early-stage pipeline work. General and administrative expenses increased to $79.6 million from $68.9 million.
Cash, cash equivalents and marketable securities were $586.0 million as of December 31, 2025, and pro forma cash including first-quarter 2026 at-the-market share sales was $716.0 million. The company raised $242.2 million through its at-the-market facility and expects its cash to fund operations into the second half of 2027, while key Phase 3 azetukalner data readouts begin in March 2026.
Xenon Pharmaceuticals (XENE) furnished an update on its latest results. The company announced financial results for the three and nine months ended September 30, 2025 via a press release attached as Exhibit 99.1. The information under Item 2.02 and the exhibit are furnished, not filed with the SEC.
Xenon also notes it shares material updates through SEC filings, press releases, conference calls, its websites, and official social media channels.
Xenon Pharmaceuticals (XENE) appointed Thomas (Tucker) Kelly as Chief Financial Officer, effective October 15, 2025. He becomes the company’s principal financial and accounting officer, bringing prior CFO experience at Deciphera Pharmaceuticals and earlier roles across life sciences finance, banking, and law.
Under his employment terms, Mr. Kelly will receive a $540,000 annual base salary and is eligible for an annual incentive of up to 45% of base salary. He will receive a one-time grant of 225,000 options and 30,000 RSUs under the 2025 Inducement Equity Incentive Plan. Severance terms include up to 18 months of base salary depending on tenure, pro-rated Average Bonus, retirement contribution equivalents for the severance period, and equity vesting and exercisability provisions, with enhanced benefits upon a qualifying termination during a change of control period. Ian Mortimer ceases interim CFO duties and continues as President and CEO.
Xenon Pharmaceuticals appointed Thomas (Tucker) Kelly as Chief Financial Officer, effective October 15, 2025. He becomes the company’s principal financial and accounting officer, bringing prior CFO experience from Deciphera Pharmaceuticals and earlier leadership roles across life sciences finance and banking. Ian Mortimer will cease serving as interim CFO and continues as President and CEO.
Kelly’s employment terms include a $540,000 annual base salary, an annual incentive opportunity up to 45% of base salary, a one-time grant of 225,000 stock options, and 30,000 RSUs under the 2025 Inducement Plan. If terminated without cause outside a change of control period, severance equals 12 months of base salary plus one month per year of service (capped at 18 months), pro‑rated Average Bonus, retirement contributions for the severance period, and limited continued vesting and exercisability. During a change of control period, severance includes 100% target bonus, full vesting acceleration, and extended exercisability as outlined.
Xenon Pharmaceuticals Inc. announced via press release dated August 11, 2025 that it is furnishing its financial results for the three and six months ended June 30, 2025. The press release is attached as Exhibit 99.1 and, per the filing, the information is furnished to the SEC rather than filed.
The company reiterates that it distributes material information through SEC filings, press releases, conference calls, its corporate and investor websites, and social media channels. The filing identifies the company trading as XENE on the Nasdaq Global Market and is signed by Ian Mortimer, Chief Executive Officer and Interim Chief Financial Officer.